m-TOR inhibitors: Biology and use in the treatment of haematological diseases;Inhibiteurs de mTOR: De l'explication biologique à l'application thérapeutique en hématologie

Bulletin du Cancer

Volumn 98, Issue 8, 2011, Pages 935-943

  Balsat, Marie ^a   Cornillon, Jérôme ^a  

^a Institut de Cancerologie de la Loire   (France)

Author keywords

Biology; Everolimus; Haematology diseases; mTOR inhibitors; Temsirolimus

Indexed keywords

CYTOKINE; GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; RAPAMYCIN; RAPAMYCIN DERIVATIVE; CRTC2 PROTEIN, HUMAN; MTORC1 COMPLEX, HUMAN; PROTEIN; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR;

AUTOPHAGY; CANCER RESEARCH; CELL GROWTH; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG RESEARCH; HEMATOLOGIC MALIGNANCY; HUMAN; METABOLISM; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; HEMATOLOGIC DISEASE; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; PHYSIOLOGY;

ENZYME ACTIVATION; HEMATOLOGIC DISEASES; HUMANS; LEUKEMIA; LYMPHOMA; MULTIPLE MYELOMA; PROTEINS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 80052606556     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1413     Document Type: Review

References (53)

1. Panwalkar A., Verstovsek S., Giles F.J. Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 2004; 100 : 657-666 (Pubitemid 38176841)
2. Brown E.J., Albers M.W., Shin T.B., et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369 : 756-758
3. Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., Snyder S.H. RAFT1: A mammalian protein that binds to FKBP 12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994; 78 : 35-43. (Pubitemid 24228298)
4. Costa L.J. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma. Cancer Treat Rev 2007; 33 : 78-84. (Pubitemid 46132007)
5. Heitman J., Movva N.R., Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 1991; 253 : 905-909 (Pubitemid 21917235)
6. Sabers C.J., Martin M.M., Brunn G.J., et al. Isolation of a protein target of the FKBP 12-rapamycin complex in mammalian cells. J Biol Chem 1995; 270 : 815-822
7. Teachey D.T., Grupp S.A., Brown V.I. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009; 145 : 569-580
8. Dancey J. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol 2010; 7 : 209-219
9. Park S., Chapuis N., Tamburini J., et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 2010; 95 : 819-828
10. Gwinn D.M., Shackelford D.B., Egan D.F., et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 2008; 30 : 214-226 (Pubitemid 351626684)
11. Laplante M., Sabatini D.M. mTOR signaling at a glance. J Cell Sci 2009; 122(Pt 20) : 3589-3594
12. Csibi A., Cornille K., Leibovitch M.P., et al. The translation regulatory subunit eIF3f controls the kinase-dependent mTOR signaling required for muscle differentiation and hypertrophy in mouse. PLoS One 2010; 5 : e8994.
13. Peterson T.R., Laplante M., Thoreen C.C., et al. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137 : 873-886
14. Hidalgo M., Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19 : 6680-6686 (Pubitemid 32197708)
15. Chapuis N., Tamburini J., Green A.S., et al. Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia 2010; 24 : 1686-1699
16. Gibbons J.J., Abraham R.T., Yu K. Mammalian target of rapamycin: Discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. Semin Oncol 2009; 36(Suppl. 3) : S3-17.
17. Zhao Y., Wang L., Yang J., et al. Anti-neoplastic activity of the cytosolic FoxO1 results from autophagic cell death. Autophagy 2010; 6 : 988-990
18. Kurmasheva R.T., Huang S., Houghton P.J. Predicted mechanisms of resistance to mTOR inhibitors. Br J Cancer 2006; 95 : 955-960 (Pubitemid 44606818)
19. Yilmaz O.H., Valdez R., Theisen B.K., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 441 : 475-482 (Pubitemid 44050144)
20. Yoshida H., Imamura T., Fiujiki A., et al. RAD001, an inhibotor of mTOR, enhances monocytic differenciation induced by ATRA trough phosphorylation of C/EBPa in AML cell lines. 52nd ASH Annual Meeting and Exposition 2010 [Abstract 2152].
21. Ly C., Arechiga A.F., Melo J.V., Walsh C.M., Ong S.T. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003; 63 : 5716-5722 (Pubitemid 37187466)
22. De Young M.P., Horak P., Sofer A., Sgroi D., Ellisen L.W. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 2008; 22 : 239-251
23. Eng C.P., Sehgal S.N., Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 1984; 37 : 1231-1237 (Pubitemid 14015835)
24. Douros J., Suffness M. New antitumor substances of natural origin. Cancer Treat Rev 1981; 8 : 63-87. (Pubitemid 11088289)
25. Altman J.K., Platanias L.C. Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. Curr Opin Hematol 2008; 15 : 88-94. (Pubitemid 351323147)
26. Hoang B., Frost P., Shi Y., et al. Targeting TORC2 in multiple myeloma with a new mTOR kinase inhibitor. Blood 2010; 116 : 4560-4568
27. Tamburini J., Green A.S., Bardet V., et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009; 114 : 1618-1627
28. Xu Q., Thompson J.E., Carroll M. mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood 2005; 106 : 4261-4268 (Pubitemid 41775935)
29. Recher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acutemyeloid leukemia. Blood 2005; 105 : 2527-2534 (Pubitemid 40387055)
30. Wei A.H., Sadawarte S., Catalano J., et al. A phase Ib study combining the mTOR inhibitor Everolimus (RAD001) with low-dose cytarabine in un treated elderly AML. 52nd ASH Annual Meeting and Exposition 2010 [Abstract 3299].
31. Amadori S., Venditti A., Ammatuna E., et al. Temsirolimus, an mTOR inhibitor, in comination with low-dose clofarabine in older patients with advanced acute myeloid leukemia: results of a phase 2 GIMENA study (AML-1107). 52nd ASH Annual Meeting and Exposition 2010 [Abstract 510].
32. Yee K.W., Zeng Z., KonoplevaM., et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006; 12 : 5165-5173 (Pubitemid 44453345)
33. Teachey D.T., Sheen C., Hall J., et al. mTOR inhibitors are synergistic with methotrexate: An effective combination to treat acute lymphoblastic leukemia. Blood 2008; 112 : 2020-2023
34. Wei G., Twomey D., Lamb J., et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006; 10 : 331-342 (Pubitemid 44512194)
35. Hess G., Herbrecht R., Romaguera J., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27 : 3822-3829
36. O'Connor O.A., Popplewell L., Winter J.N., et al. PILLAR-1: preliminary results of a phase II study of mTOR inhibitor everolimus in patients with mantle cell lymphoma (MCL) who are refractory or intolerant to bortezomib. 52nd ASH Annual Meeting and Exposition 2010 [Abstract 3963].
37. Renner C., Zinzani P.L., Gressin R., et al. A multi-center phase II study (SAKK 36/06) of single agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. 52nd ASH Annual Meeting and Exposition 2010 [Abstract 2803].
38. Smith S.M., Van Besien K., Karrison T., et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010; 28 : 4740-4746
39. Johnston P.B., Inwards D.J., Colgan J.P., et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85 : 320-324
40. Kumar S., Porrata L.F., Ansell S.M., et al. Phase 1 trial of sorafenib ans everolimus in patients with lymphoma or multiplemyeloma. 52nd ASH Annual Meeting and Exposition 2010 [Abstract 2802].
41. Decker T., Hipp S., Ringshausen I., et al. Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin. Blood 2003; 101 : 278-285 (Pubitemid 36025919)
42. Zent C.S., La Plant B.R., Johnston P.B., et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer 2010; 116 : 2201-2207
43. Ghobrial I.M., Gertz M., Laplant B., et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010; 28 : 1408-1414
44. Farag S.S., Zhang S., Jansak B.S., et al. Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma. Leuk Res 2009; 33 : 1475-1480
45. Ghobrial I.M., Weller E., Vij R., et al. Final results of the Phase I/II trial of weekly bortezomib in combination with temsirolimus (CCI- 779) in relapsed or reaplsed/refractory multiple myeloma specifically in patients refractory to bortezomib. 52nd ASH Annual Meeting and Exposition 2010 [Abstract 990].
46. Maiso P., Azab A., Liu Y., et al. Dual targeting of -TORC1 and - TORC2 as a new strategy in the treatmetn of multiple myeloma. 52nd ASH Annual Meeting and Exposition 2010 [Abstract 133].
47. Sillaber C., Mayerhofer M., Bohm A., et al. Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia. Eur J Clin Invest 2008; 38 : 43-52. (Pubitemid 350293855)
48. Kuwatsuka Y., Minami Y., Minami M., Tanizaki R., Kiyoi H., Naoe T. Treatment with mTOR inhibitor, everolimus (RAD001) overcomes resistance to imatinib in Ph-leukemia quiescent cells. 52nd ASH Annual Meeting and Exposition 2010 [Abstract 1579].
49. Mehrabi A., Fonouni H., Kashfi A., et al. The role and value of sirolimus administration in kidney and liver transplantation. Clin Transplant 2006; 20(Suppl. 17) : 30-43. (Pubitemid 44697898)
50. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 2001; 72 : 1924-1929 (Pubitemid 34027865)
51. Jurado M., Vallejo C., Perez-Simon J.A., et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13 : 701-706 (Pubitemid 46767997)
52. Armand P., Gannamaneni S., Kim H.T., et al. Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol 2008; 26 : 5767-5774
53. Tee A.R., Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2005; 16 : 29-37. (Pubitemid 40126874)